Leveraging our cutting-edge technology based on protein dynamics, Nutshell is fostering a new
era of drug discovery…
Our AlloStar allosteric drug discovery platform, composed of a
powerful and well-integrated set of computational modules and experimental tools based on our proprietary
AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the unique capability
to discover a host of drug entities including various types of protein activators, subtype/mutation
selective small molecules, regulatory molecules of protein-protein interaction (PPI) and stabilizer of
intrinsically disordered proteins (IDPs), thus opening up an unprecedented new horizon for small molecule
innovation.
-
Sub-type selective allosteric inhibitor
-
Mutants selective allosteric inhibitor
-
Enzyme allosteric activator
-
Protein-protein interaction modulator
-
Disordered protein stabilize modulator
Current Pipeline
Project | MoA | Indications | Discovery | Lead to PCC | IND enabling | Phase I/II | Phase III |
---|---|---|---|---|---|---|---|
p53 Y220C | Allosteric activator | Solid tumor |
|
||||
N009 (BIC) | Allosteric inhibitor | Solid tumor |
|
||||
N017 (BIC) | Allosteric inhibitor | Solid tumor |
|
||||
N019 (BIC) | Allosteric inhibitor | Solid tumor |
|
||||
N001 (FIC) | Allosteric activator | Metabolism |
|
||||
Potential FIC projects of various disease targets |
|
Our Lab
Building E, No.1976 Middle Gaoke Rd. Pudong District, Shanghai, China
contact@allonutshell.com;BD@allonutshell.com
Back
to the top